Chronic heart failure therapeutic pipeline will increase in near future due to increasing cases of the disease. The prevalence of chronic heart failure is increasing globally due to the factors including obesity, diabetes, high blood pressure, cholesterol, less physical activity and tobacco consumption. These factors are contributing in driving the pipeline analysis for chronic heart failure. According to Centers for Disease Control and Prevention, around 5.7 million adults in the U.S. have heart failure and about half of people die within five years of diagnosis. Asthma is equally prevalent in women than in men.
Chronic heart failure is a condition, in which heart muscles gets damaged and cannot pump blood properly. This condition slows down the rate of blood flow and increases the pressure, resulting in insufficient supply of oxygen and nutrients to the body. The damage can be a result of heart attack or long-term health issues like diabetes, high blood pressure and heart disease. Heart failure can be caused by several conditions including heart attack, coronary artery disease, thyroid, kidney disease and cardiomyopathy. Some of the symptoms of chronic heart failure include lung congestion, dizziness, fluid and water retention, fatigue, irregular heartbeats and weakness. Chronic heart failure is categorized into two types, systolic dysfunction and diastolic dysfunction. Heart failure is diagnosed by analysing patient’s medical history and examining the symptoms. Also, alcohol consumption, smoking and drugs intake are considered while diagnosing the disease. Certain tests are also conducted for confirmation which includes blood tests, chest X-ray, B-type natriuretic peptide blood test, electrocardiogram, echocardiogram, cardiac catheterization and the ejection fraction test. Chronic heart failure can be treated with strict medications and healthy lifestyle with regular monitoring. The treatment initially aims to decrease the symptoms and improve the quality of life of the patient.
Boehringer Ingelheim GmbH is developing a drug by the name Empagliflozin for the treatment of heart failure. Empagliflozin is a small molecule that inhibits sodium-glucose transporter 2 and is in the Phase III stage of development. Janssen Research & Development, LLC with Bayer AG is in the process of developing Rivaroxaban, which is in the Phase III stage of clinical trial. Rivaroxaban is a small molecule, which inhibits factor IX and Xa. Bayer AG is in the process of developing BAY1067197 for the treatment of chronic heart failure. It is currently in Phase II stage of development and acts as an adenosine A1 receptor agonists. GlaxoSmithKline plc is developing GSK2798745, which is in Phase II stage of development. It inhibits transient receptor potential cation channel subfamily V member 4 (TRPV4) protein. Sulfagenix Australia Pty Ltd. is developing SG1002 which is being developed to be administered as a capsule.
Some of the companies having a pipeline of chronic heart failure therapeutics include Amgen, Inc., Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sulfagenix Australia Pty Ltd., Janssen Research & Development, LLC, AstraZeneca plc, Bristol-Myers Squibb Company, MorphoSys AG.